Solifenacin
Drugs For Urinary Frequency and Incontinence
- Drug class
- Drugs For Urinary Frequency and Incontinence
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 123
Overview
Plain-language summary, compiled from the cited regulatory records
Solifenacin is a medication classified as a muscarinic antagonist [1]. It is approved for the treatment of adults experiencing overactive bladder [1]. The symptoms associated with this condition that solifenacin addresses include urge urinary incontinence, urgency, and urinary frequency [1].
Solifenacin is available in tablet form and is marketed under various brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 113 | May 15, 2026 |
| CA Canada | Health Canada | 8 | February 10, 2026 |
| US United States | FDA | 2 | January 28, 2026 |
GBUnited Kingdom· MHRA
113 products
Uses
Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.
How to take
CACanada· Health Canada
8 products
Uses
…………....
How to take
USUnited States· FDA
2 products
Uses
1 INDICATIONS AND USAGE Solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin succinate tablets are a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency ( 1 ).
How to take
Drug interactions
Known interactions involving Solifenacin. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 428. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL317500148 · revised August 13, 2024
- [2]Health Canada (DPD) · 02403595 · revised February 10, 2026
- [3]FDA DailyMed · 010c0657-c907-47… · revised January 28, 2026 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.